Asthma and Cardiovascular Diseases: Navigating Mutual Pharmacological Interferences.

Autor: Cazzola M; Unit of Respiratory Medicine, Department of Experimental Medicine, University of Rome 'Tor Vergata', Rome, Italy. mario.cazzola@uniroma2.it., Page CP; Institute of Pharmaceutical Science, King's College London, London, UK., Hanania NA; Section of Pulmonary and Critical Care Medicine, Baylor College of Medicine, Houston, TX, USA., Calzetta L; Department of Medicine and Surgery, Respiratory Disease and Lung Function Unit, University of Parma, Parma, Italy., Matera MG; Unit of Pharmacology, Department of Experimental Medicine, University of Campania 'Luigi Vanvitelli', Naples, Italy., Rogliani P; Unit of Respiratory Medicine, Department of Experimental Medicine, University of Rome 'Tor Vergata', Rome, Italy.
Jazyk: angličtina
Zdroj: Drugs [Drugs] 2024 Oct; Vol. 84 (10), pp. 1251-1273. Date of Electronic Publication: 2024 Sep 26.
DOI: 10.1007/s40265-024-02086-5
Abstrakt: Asthma and cardiovascular disease (CVD) often co-exist. When a patient has both conditions, management requires an approach that addresses the unique challenges of each condition separately, while also considering their potential interactions. However, specific guidance on the management of asthma in patients with CVD and on the management of CVD in patients with asthma is still lacking. Nevertheless, health care providers need to adopt a comprehensive approach that includes both respiratory and CVD health. The management of CVD in patients with asthma requires a delicate balance between controlling respiratory symptoms and minimising potential cardiovascular (CV) risks. In the absence of specific guidelines for the management of patients with both conditions, the most prudent approach would be to follow established guidelines for each condition independently. Careful selection of asthma medications is essential to avoid exacerbation of CV symptoms. In addition, optimal management of CV risk factors is essential. However, close monitoring of these patients is important as there is evidence that some asthma medications may have adverse effects on CVD and, conversely, that some CVD medications may worsen asthma symptoms. On the other hand, there is also increasing evidence of the potential beneficial effects of asthma medications on CVD and, conversely, that some CVD medications may reduce the severity of asthma symptoms. We aim to elucidate the potential risks and benefits associated with the use of asthma medications in patients with CVD, and the potential pulmonary risks and benefits for patients with asthma who are prescribed CVD medications.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: